Peptide immunotherapy for allergic disease

Expert Opinion on Biological Therapy

Volumn 3, Issue 4, 2003, Pages 617-626

  Tarzi, Michael ^a   Larché, Mark ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergy; Immunotherapy; Peptide; T cell

Indexed keywords

EPITOPE; FEL D 1 PEPTIDE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE IPC1; PEPTIDE IPC2; PHOSPHOLIPASE A2; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC DISEASE; ANIMAL CELL; B LYMPHOCYTE; BIODIVERSITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; EPITOPE MAPPING; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN INTERACTION; REVIEW; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; CLINICAL TRIALS; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; PEPTIDES;

ANIMALIA;

EID: 0038603844     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.4.617     Document Type: Review

References (76)

1. BABU KS, ARSHAD SH, HOLGATE ST: Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin. Biol. Ther. (2001) 1:1049-1058.
2. BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. (2001) 107:963-970.
3. LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2144-2148.
4. FLOOD-PAGE PT, MENZIES-GOW AN, KAY AB, ROBINSON DS: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. (2003) 167:199-204.
5. NOON L: Prophylactic innoculation against hay fever. Lancet (1911):1572-1573.
6. BOUSQUET J, LOCKEY R, MALLING HJ et al.: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol (1998) 81:401-405. A comprehensive overview of SIT.
7. WALKER SM, VARNEY VA, GAGA M, JACOBSON MR, DURHAM SR: Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy (1995) 50:405-413.
8. VARNEY VA, EDWARDS J, TABBAH K, BREWSTER H, MAVROLEON G, FREW AJ: Clinical efficacy of specific immunotherapy to cat dander. a double-blind placebo-controlled trial. Clin. Exp. Allergy (1997) 27:860-867.
9. HUNT KJ, VALENTINE MD, SOBOTKA AK, BENTON AW, AMODIO FJ, LICHTENSTEIN LM: A controlled trial of immunotherapy in insect hypersensitivity. N. Engl. J. Med (1978) 299:157-161.
10. DURHAM SR, WALKER SM, VARGA EM, JACOBSON MR, O'BRIEN F, NOBLE W et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. (1999) 341:468-475.
11. WALKER SM, PAJNO GB, LIMA MT, WILSON DR, DURHAM SR: Grass pollen immunotherapy for seasonal allergic rhinitis and asthma. J. Allergy Clin. Immunol. (2001) 107:87-93.
12. PURELLO-D'AMBROSIO F, GANGEMI S, MERENDINO RA et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy (2001) 31:1295-1302.
13. VAN DER VEEN MJ, MULDER M, WITTEMAN AM et al.: False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J. Allergy Clin. Immunol. (1996) 8:1028-1034.
14. MAGGI E, DEL PRETE GF, TIRI A et al.: T cell clones providing helper function for IgE synthesis release soluble factor(s) that induce IgE production in human B cells: possible role for interleukin 4 (IL-4). Clin. Exp. Immunol. (1988) 73:57-62.
15. PUNNONEN J, AVERSA G, COCKS BG et al.: Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Natl. Acad. Sci. USA (1993) 90:3730-3734.
16. CLUTTERBUCK EJ, HIRST EM, SANDERSON CJ: Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood (1989) 73:1504-1512.
17. TILL S, DICKASON R, HUSTON D et al.: IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: relationship to expression of allergic disease. J. Allergy Clin. Immunol. (1997) 99:563-569.
18. ROBINSON DS, HAMID Q, YING S et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. (1992) 326:298-304.
19. VARNEY VA, JACOBSON MR, SUDDERICK RM et al.: Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am. Rev. Respir. Dis. (1992) 146:170-176.
20. POULTER LW, POWER C, BURKE C: The relationship between bronchial immunopathology and hyperresponsiveness in asthma. Eur. Respir. J. (1990) 3:792-799.
21. HUMBERT M, CORRIGAN CJ, KIMMITT P, TILL SJ, KAY AB, DURHAM SR: Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am. J. Respir. Crit. Care Med (1997) 156:704-708.
22. HASELDEN BM, KAY AB, LARCHE M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. (1999) 189:1885-1894.
23. VAN DER HEIJDEN FL, JOOST VAN NEERVEN RJ, VAN KATWIJK M, BOS JD, KAPSENBERG ML: Serum-IgE-facilitated allergen presentation in atopic disease. J. Immunol. (1993) 150:3643-3650.
24. JUTEL M, WATANABE T, KLUNKER S et al.: Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature (2001) 413:420-425.
25. LARCHE M, TILL SJ, HASELDEN BM et al.: Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J. Immunol. (1998) 161:6375-6382.
26. DEBENEDETTE MA, SHAHINIAN A, MAK TW, WATTS TH: Costimulation of CD28-T lymphocytes by 4-1BB ligand. J. Immunol. (1997) 158:551-559.
27. TAMADA K, SHIMOZAKI K, CHAPOVAL AI et al.: LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. (2000) 164:4105-4110.
28. KUMAR V, BHARDWAJ V, SOARES L, ALEXANDER J, SETTE A, SERCARZ E: Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Proc. Natl. Acad. Sci. USA (1995) 92:9510-9514.
29. HOSKEN NA, SHIBUYA K, HEATH AW, MURPHY KM, O'GARRA A: The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. (1995) 182:1579-1584.
30. O'GARRA A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity (1998) 8:275-283.
31. LAMB JR, SKIDMORE BJ, GREEN N, CHILLER JM, FELDMANN M: Induction of tolerance in influenza virus-immune lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. (1983) 157:1434-1447.
32. HIGGINS JA, LAMB JR, MARSH SGE et al.: Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. J. Allergy Clin. Immunol. (1992) 90:749-756.
33. BRINER TJ, KUO MC, KEATING KM, ROGERS BL, GREENSTEIN JL: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci. USA (1993) 90:7608-7612.
34. HOYNE GF, O'HEHIR RE, WRAITH DC, THOMAS WR, LAMB JR: Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. (1993) 178:1783-1788. A convincing demonstration of T cell peptide desensitisation in a murine model.
35. METZLER B, WRAITH DC: Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. (1993) 5:1159-1165.
36. BROCKE S, GIJBELS K, ALLEGRETTA M et al.: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature (1996) 379:343-346.
37. ANDERTON SM, WRAITH DC: T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol. (1998) 28:1251-1261.
38. ANDERTON SM, VINER NJ, MATHARU P, LOWREY PA, WRAITH DC: Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat. Immunol. (2002) 3:175-181. A seminal illustration of cryptic epitopes.
39. TEXIER C, POUVELLE S, BUSSON M et al.: HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol (2000) 164:3177-3184.
40. SOBOTKA AK, FRANKLIN RM, ADKINSON NF JR, VALENTINE M, BAER H, LICHTENSTEIN LM: Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J. Allergy Clin. Immunol. (1976) 57:29-40.
41. CARBALLIDO JM, CARBALLIDO-PERRIG N, KAGI MK et al.: T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J. Immunol. (1993) 150:3582-3591.
42. AKDIS CA, AKDIS M, BLESKEN T et al.: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. (1996) 98:1676-1683.
43. MULLER U, AKDIS CA, FRICKER M et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. (1998) 101:747-754. The first attempt at T peptide desensitisation in human honeybee allergic patients.
44. NO AUTHORS LISTED: Position paper: immunotherapy with hymenoptera venoms (EAACI). Allergy (1993) 48:36-46.
45. FELLRATH J, KETTNER A, DUFOUR N et al.: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. (2003) 111:854-861.
46. NORMAN PS, OHMAN JL JR, LONG AA et al.: Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. (1996) 154:1623-1628.
47. MARCOTTE GV, BRAUN CM, NORMAN PS et al.: Effects of peptide therapy on ex vivo T-cell responses. J. Allergy Clin. Immunol. (1998) 101:506-513.
48. PENE J, DESROCHES A, PARADIS L et al.: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. (1998) 102:571-578.
49. MAGUIRE P, NICODEMUS C, ROBINSON D, AARONSON D, UMETSU DT: The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. (1999) 93:222-231.
50. SIMONS FE, IMADA M, LI Y, WATSON WT, HAYGLASS KT: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. (1996) 8:1937-1945.
51. HOYNE GF, ASKONAS BA, HETZEL C, THOMAS WR, LAMB JR: Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int. Immunol (1996) 8:335-342.
52. HASELDEN BM, SYRIGOU E, JONES M et al.: Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. J. Allergy Clin. Immunol. (2001) 108:349-356.
53. OLDFIELD WL, KAY AB, LARCHE M: Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. (2001) 167:1734-1739.
54. ALEXANDER C, OLDFIELD WL, SHIRLEY K, LARCHÉ M, KAY AB: A dosing protocol of allergen-derived T cell peptide epitopes for the treatment of allergic disease. J. Allergy Clin. Immunol. (2001) 107:716.
55. ALI FR, BYLANSKI M, ARBERY J, LARCHÉ M, KAY AB: Inhalation of allergen-derived T cell peptide epitopes induces isolated late asthmatic reactions with associated local eosinophilia. J. Allergy Clin. Immunol. (2002) 109:494.
56. ALI FR, ARBERY J, LARCHÉ M, KAY AB: Late asthmatic reactions provoked by intradermal, but not inhaled, allergen-derived T-cell peptides induce 'tolerance' to subsequent antigen challenge. J. Clin. Immunol. (2003) 111:850.
57. OLDFIELD WL, LARCHÉ M, KAY AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 360:47-53. An important placebo-controlled study of cat-allergic volunteers treated with peptides of Fel d 1.
58. 2 on late phase skin reactions and T cell function in subjects with mild honeybee allergy. J. Allergy Clin. Immunol. (2003) 111:519.
59. JUTEL M, PICHLER WJ, SKRBIC D, URWYLER A, DAHINDEN C, MULLER UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J. Immunol. (1995) 154:4187-4194.
60. EBNER C, SIEMANN U, BOHLE B et al.: Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy (1997) 27:1007-1015.
61. MCHUGH SM, DEIGHTON J, STEWART AG, LACHMANN PJ, EWAN PW: Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin. Exp. Allergy (1995) 25:828-838.
62. VARNEY VA, HAMID QA, GAGA M et al.: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. (1993) 92:644-651.
63. NASSER SM, YING S, MENG Q, KAY AB, EWAN PW: Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur. J. Immunol. (2001) 31:3704-3713.
64. MUELLER DL, JENKINS MK, CHIODETTI L, SCHWARTZ RH: An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal. J. Immunol. (1990) 144:3701-3709.
65. KOJJIMA A, TANAKA-KOJIMA Y, SAKAKURA T, NISHIZUKA Y: Prevention of post-thymectomy autoimmune thyroiditis in mice. Lab. Invest. (1975) 34:601-605.
66. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunological self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) - breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. (1995) 160:1151-1164.
67. THORNTON AM, SHEVACH EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. (1998) 188:287-296.
68. ASSMAN C, MAUZE S, LEACH MW, COFFMAN RL, POWRIE F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. (1999) 190:995-1003.
69. POWRIE F, CARLINO J, LEACH MW, MAUZE S, COFFMAN RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper 1-mediated colitis by CD45RB(low) CD4(+) T cells. J. Exp. Med. (1996) 183:2669-2674.
70. SHEVACH EM: Certified professionals: CD4(+)CD25(+) suppressor T cells. J. Exp. Med. (2001) 193(11):F41-F46. An excellent overview of the field of regulatory T cells.
71. AKDIS CA, BLESKEN T, AKDIS M, WUTHRICH B, BLASER K: Role of interleukin 10 in specific immunotherapy. (1998) J. Clin. Invest 102:98-106. Important work concerning the mechanisms of bee venom immunotherapy.
72. AKDIS CA, BLASER K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. (1999) 13:603-609.
73. AKDIS CA, JOSS A, AKDIS M, BLASER K: Mechanism of IL-10-induced T cell inactivation in allergic inflammation and normal response to allergens. Int. Arch. Allergy Immunol. (2001) 124:180-182.
74. ALEXANDER C, BARKANS J, FORSYTH L et al.: Allergen-derived T-cell peptide immunotherapy in allergic asthmatic individuals is associated with induction of CD4+ IFN-gamma+/CD4+CD25+ T cells and enhanced expression of TGF-beta and Notch-1 ligands at sites of cutaneous allergen challenge. J. Allergy Clin. Immunol. (2003) 111:518.
75. BALL T, FUCHS T, SPERR WR et al.: B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. (1999) 13:1277-1290.
76. BALL T, SPERR WR, VALENT P et al: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. (1999) 29:2026-2036.